Compare McCormick & Company, Incorporated (MKC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Sanofi SA — how do they compare? McCormick & Company, Incorporated trades at $45.94 (market cap $12.39B), while Sanofi SA trades at $40.2 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 7.7× McCormick & Company, Incorporated's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Sanofi SA for 94 Days on average.
| MKC | SNY | |
|---|---|---|
Market Cap | $12.39B | $95.18B |
Volume | 6,140,872 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $52.34 |
52-Week Low | $44.14 | $39.51 |
Typical Hold Time | 67 Days | 94 Days |
Enterprise Value | $17.07B | $114.48B |
Dividend Yield | 4.18% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $45.25, down 0.33% with a bearish technical signal despite strong Q3 2026 earnings that beat estimates. The stock shows attractive valuation metrics with a P/E of 8.18 and robust profitability including 19.39% net income margin. Recent performance reflects 17% sales growth driven by the Mexico acquisition and margin expansion, though technical indicators suggest near-term pressure with support at $44.
MKC presents a compelling value opportunity with below-sector P/E ratio and consistent dividend payments, though bearish technicals and mixed analyst sentiment (33% buy, 60% hold) indicate caution. Upside potential exists to the $53.50 consensus target, but investors face risks from integration challenges and macroeconomic pressure on consumer spending.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
